APH 1701
Alternative Names: APH-1701Latest Information Update: 22 May 2024
At a glance
- Originator Aphios Corporation
- Class Antivirals; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical HIV-1 infections
Most Recent Events
- 16 May 2024 Aphios Corporation has patent protection for CCR5 and CD4 siRNA-targeted therapeutics for the treatment of HIV-1 infections
- 25 Nov 2021 Aphios Corporation has patent pending protection for APH 1701 in undisclosed countries (Aphios Corporation pipeline, November 2021)
- 25 Nov 2021 Aphios Corporation pipeline has patent protection for APH 1701 in USA (Aphios Corporation pipeline, November 2021)